Early Combination Therapy vs Stepwise Escalation in Newly Diagnosed Type 2 Diabetes: A Systematic Review and...

Our aim in this study was to evaluate efficacy, durability, and safety of early combination therapy compared with stepwise escalation in newly diagnosed type 2 diabetes. We searched PubMed, Cochrane Central Register of Controlled Trials, and Embase through November 2025 for trials comparing early combination therapy with stepwise escalation in treatment-naive patients. Outcomes included A1C reduction, time to treatment failure, beta-cell function, hypoglycemia, weight change, cardiovascular risk markers, and hepatic outcomes. The random-effects meta-analysis used the inverse variance method. Eleven studies (24,364 participants) were included. Early combination therapy achieved greater glycated hemoglobin reduction vs stepwise escalation (mean difference -0.49%, 95% confidence interval -0.53 to -0.45, p<0.001) and nearly doubled time to treatment failure (61.9 vs 36.1 months; hazard ratio 0.51, p<0.0001). Beta-cell function was preserved for 3.5 years with early combination therapy, as compared with a progressive decline with stepwise therapy. Early combination therapy demonstrated a 7.5-fold lower incidence of hypoglycemia, favourable effects on weight (5.3-kg difference), reduced carotid atherosclerosis progression, improved blood pressure and lipid profiles, and reduced hepatic fat accumulation. Early combination therapy is superior to stepwise escalation in glycemic management, durability, beta-cell preservation, safety, and cardiovascular risk reduction, thereby supporting disease modification rather than merely symptomatic control.